{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:01:51Z","timestamp":1790146911387,"version":"4.0.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2008,8,22]],"date-time":"2008-08-22T00:00:00Z","timestamp":1219363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>For 40 years prophylactic anti-D has been given to D-negative women after parturition to prevent haemolytic disease of the fetus and newborn. Monoclonal or recombinant anti-D may provide alternatives to the current plasma-derived polyclonal IgG anti-D, although none of them have yet proved as effective in phase 1 clinical trials. The variation in efficacy of the antibodies may have been influenced by heterogeneity in glycosylation of anti-D produced from different cell lines. Some aspects of the conduct of the human studies, most notably the use of low doses of anti-D and target D positive red cells in vivo, may aid the design of the clinical development of other immunomodulatory drugs in order to minimize adverse effects.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2008.03735.x","type":"journal-article","created":{"date-parts":[[2008,10,11]],"date-time":"2008-10-11T13:04:42Z","timestamp":1223730282000},"page":"1-5","source":"Crossref","is-referenced-by-count":47,"title":["Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn"],"prefix":"10.1093","volume":"154","author":[{"given":"B M","family":"Kumpel","sequence":"first","affiliation":[{"name":"Bristol Institute for Transfusion Sciences, International Blood Group Reference Laboratory, National Blood Service, NHS Blood and Transplant, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,8,22]]},"reference":[{"key":"2022010405084944900_b1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2249.2007.03559.x","article-title":"Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412","volume":"151","author":"Dayan","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"2022010405084944900_b2","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/j.0041-1132.2003.00632.x","article-title":"Thirty-five years of Rh prophylaxis","volume":"43","author":"Bowman","year":"2003","journal-title":"Transfusion"},{"key":"2022010405084944900_b3","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1182\/blood.V78.10.2747.2747","article-title":"Genetic basis of the RhD-positive and RhD-negative blood group polymorphism as determined by Southern analysis","volume":"78","author":"Colin","year":"1991","journal-title":"Blood"},{"key":"2022010405084944900_b4","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1136\/bmj.1.5238.1486","article-title":"Experimental studies on the prevention of Rh haemolytic disease","volume":"1","author":"Finn","year":"1961","journal-title":"BMJ"},{"key":"2022010405084944900_b5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1537-2995.1964.tb02824.x","article-title":"Successful prevention of experimental Rh sensitization in man with an anti-Rh gamma2-globulin antibody preparation. A preliminary report","volume":"4","author":"Freda","year":"1964","journal-title":"Transfusion"},{"key":"2022010405084944900_b6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2004.04804.x","article-title":"Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by Fc\u03b3RIIa and Fc\u03b3RIIIa polymorphisms","volume":"124","author":"Cooper","year":"2004","journal-title":"Br J Haematol"},{"key":"2022010405084944900_b7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1471-4906(00)01801-9","article-title":"Mechanism of anti-D-mediated immune suppression \u2013 a paradox awaiting resolution?","volume":"22","author":"Kumpel","year":"2001","journal-title":"Trends Immunol"},{"key":"2022010405084944900_b8","first-page":"87","article-title":"The estimation of fetomaternal haemorrhage. BCSH Blood Transfusion and Haematology Task Forces","volume":"9","author":"Guidelines","year":"1999","journal-title":"Transfus Med"},{"key":"2022010405084944900_b9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2141.1976.tb00935.x","article-title":"The primary Rh0(D) response in male volunteers","volume":"32","author":"Gunson","year":"1976","journal-title":"Br J Haematol"},{"key":"2022010405084944900_b10","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/j.1537-2995.2006.00924_1.x","article-title":"On the immunologic basis of Rh immune globulin (anti-D) prophylaxis","volume":"46","author":"Kumpel","year":"2006","journal-title":"Transfusion"},{"key":"2022010405084944900_b11","first-page":"1","article-title":"Rh immunization and its prevention","volume":"3","author":"Woodrow","year":"1970","journal-title":"Ser Haematol"},{"key":"2022010405084944900_b12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1423-0410.1986.tb00226.x","article-title":"Fetomaternal transplacental hemorrhage during pregnancy and after delivery","volume":"51","author":"Bowman","year":"1986","journal-title":"Vox Sang"},{"key":"2022010405084944900_b13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1423-0410.2007.00945.x","article-title":"Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers","volume":"93","author":"Kumpel","year":"2007","journal-title":"Vox Sang"},{"key":"2022010405084944900_b14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1246-7820(01)00215-4","article-title":"Section 1C: assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report","volume":"9","author":"Kumpel","year":"2002","journal-title":"Transfus Clin Biol"},{"key":"2022010405084944900_b15","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V86.5.1701.bloodjournal8651701","article-title":"Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers","volume":"86","author":"Kumpel","year":"1995","journal-title":"Blood"},{"issue":"1","key":"2022010405084944900_b16","first-page":"8","article-title":"A multi-centre trial of monoclonal anti-D in the prevention of Rh-immunisation of RhD- male volunteers by RhD+ red cells","volume":"10","author":"Smith","year":"2000","journal-title":"Transfus Med"},{"key":"2022010405084944900_b17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2249.1994.tb06600.x","article-title":"Plasma half-lives and bioavailability of human monoclonal Rh D antibodies BRAD-3 and BRAD-5 following intramuscular injection into Rh D-negative volunteers","volume":"98","author":"Goodrick","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"2022010405084944900_b18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2249.2007.03458.x","article-title":"The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodies","volume":"150","author":"Chapman","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"2022010405084944900_b19","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1182\/blood-2003-11-3929","article-title":"A single recombinant anti-RhD IgG prevents Rhesus D immunization: association of RhD positive red blood cell clearance rate with polymorphisms in the Fc\u03b3RIIA and IIIA genes","volume":"103","author":"Miescher","year":"2004","journal-title":"Blood"},{"key":"2022010405084944900_b20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.0958-7578.2004.0493.x","article-title":"Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers","volume":"14","author":"Bichler","year":"2004","journal-title":"Transfus Med"},{"key":"2022010405084944900_b21","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0140-6736(90)92767-C","article-title":"Clearance of Rh D-positive red cells with monoclonal anti-D","volume":"336","author":"Thomson","year":"1990","journal-title":"Lancet"},{"key":"2022010405084944900_b22","first-page":"77","article-title":"Fast clearance of Rhesus positive erythrocytes by monoclonal anti-Rhesus antibodies \u2013 insufficient condition for effective prevention of Rhesus sensitization","volume":"129","author":"Olovnikova","year":"2000","journal-title":"J Exp Biol Med"},{"key":"2022010405084944900_b23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tracli.2006.03.013","article-title":"Monoclonal antibodies to prevent alloimmunization: lessons from clinical trials","volume":"13","author":"B\u00e9liard","year":"2006","journal-title":"Transfus Clin Biol"},{"key":"2022010405084944900_b24","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2005-03-0989","article-title":"Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity","volume":"107","author":"Armour","year":"2006","journal-title":"Blood"},{"key":"2022010405084944900_b25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2141.2008.06985.x","article-title":"A human anti-D monoclonal antibody selected for enhanced Fc\u03b3RIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies","volume":"141","author":"B\u00e9liard","year":"2008","journal-title":"Br J Haematol"},{"key":"2022010405084944900_b26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0003-9861(91)90144-8","article-title":"Structural study of the sugar moieties of monoclonal antibodies secreted by human-mouse hybridoma","volume":"291","author":"Tandai","year":"1991","journal-title":"Arch Biochem Biophys"},{"key":"2022010405084944900_b27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/glycob\/10.5.477","article-title":"Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics","volume":"10","author":"Raju","year":"2000","journal-title":"Glycobiology"},{"key":"2022010405084944900_b28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1126\/science.1068883","article-title":"Decoding the patterns of self and nonself by the innate immune system","volume":"296","author":"Medzhitov","year":"2002","journal-title":"Science"},{"key":"2022010405084944900_b29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/0167-5699(93)90261-I","article-title":"Interaction of the natural anti-Gal antibody with \u03b1-galactosyl epitopes: a major obstacle for xenotransplantation in humans","volume":"14","author":"Galili","year":"1993","journal-title":"Immunol Today"},{"key":"2022010405084944900_b30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/abio.1997.2036","article-title":"Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal \u03b1-linked galactose","volume":"247","author":"Sheeley","year":"1997","journal-title":"Anal Biochem"},{"key":"2022010405084944900_b31","first-page":"1109","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose. New Engl","volume":"358","author":"Chung","year":"2008","journal-title":"J Med"},{"key":"2022010405084944900_b32","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"2022010405084944900_b33","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2004-11-4303","article-title":"Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinurea following Rho (D) immune globulin intravenous administration for immune thrombocytopenic purpura","volume":"106","author":"Gaines","year":"2005","journal-title":"Blood"},{"key":"2022010405084944900_b34","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1182\/blood-2006-03-004481","article-title":"A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP)","volume":"109","author":"Tarantino","year":"2007","journal-title":"Blood"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2008.03735.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2008.03735.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/154\/1\/1\/42040518\/j.1365-2249.2008.03735.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/154\/1\/1\/42040518\/j.1365-2249.2008.03735.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:11:21Z","timestamp":1641255081000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/154\/1\/1\/6457351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,8,22]]},"published-print":{"date-parts":[[2008,9,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2008.03735.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,10]]},"published":{"date-parts":[[2008,8,22]]}}}